Causes and consequences of lipoprotein(a) abnormalities in kidney disease

被引：0
作者：
Florian Kronenberg
机构：
[1] Innsbruck Medical University,Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology
来源：
Clinical and Experimental Nephrology | 2014年 / 18卷
关键词：
Lipoprotein(a); Apolipoprotein(a); Genetics; Chronic kidney disease; Cardiovascular disease; Risk factor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Lipoprotein(a) is one of the strongest genetically determined risk factors for cardiovascular disease, and patients with chronic kidney disease have major disturbances in lipoprotein(a) metabolism. Concentrations are increased and are influenced by glomerular filtration rate (GFR) and the amount of proteinuria. The reason for this elevation can be increased synthesis, as is the case for patients with nephrotic syndrome or those treated by peritoneal dialysis. In hemodialysis patients, a catabolic block is the reason for this elevation. The elevated concentrations might contribute to the tremendous cardiovascular risk in this particular population. In particular, the genetically determined small apolipoprotein(a) isoforms are associated with an increased risk for cardiovascular events and total mortality.
引用
收藏
页码：234 / 237
页数：3
相关论文
共 114 条
[11]  
Perry PL(2010)Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events J Am Coll Cardiol 56 946-955
[12]  
Sandholzer C(2008)The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity Curr Opin Lipidol 19 369-377
[13]  
Saha N(1997)Renovascular arteriovenous differences in Lp(a) plasma concentrations suggest removal of Lp(a) from the renal circulation J Lipid Res 38 1755-1763
[14]  
Kark JD(1996)Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine J Clin Invest 98 2414-2424
[15]  
Sandholzer C(1996)Urinary excretion of apo(a) fragments. Role in apo(a) catabolism Arterioscler Thromb Vasc Biol 16 905-911
[16]  
Hallman DM(2000)Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure J Am Soc Nephrol 11 105-115
[17]  
Saha N(1993)Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a) J Clin Invest 91 397-401
[18]  
Kraft HG(1995)Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis J Am Soc Nephrol 6 110-120
[19]  
Lingenhel A(1998)Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure Kidney Int 53 1336-1342
[20]  
Köchl S(1999)Inflammation enhances cardiovascular risk and mortality in hemodialysis patients Kidney Int 55 648-658
12345678910